Analyst Price Targets — ELUT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 21, 2024 8:43 am | Frank Takkinen | Loop Capital Markets | $10.00 | $3.50 | StreetInsider | Aziyo Biologics Inc. (ELUT) PT Raised to $10 at Lake Street Capital Markets |
| May 10, 2024 8:11 am | Ross Osborn | Cantor Fitzgerald | $5.00 | $3.29 | TheFly | Elutia price target lowered to $5 from $6 at Cantor Fitzgerald |
| November 16, 2022 9:52 am | — | Truist Financial | $10.00 | $7.64 | Benzinga | Truist Securities Maintains Buy on Aziyo Biologics, Raises Price Target to $10 |
| November 14, 2022 9:11 pm | Matt O'Brien | Piper Sandler | $10.50 | $8.20 | TheFly | Aziyo Biologics price target raised to $10.50 from $9 at Piper Sandler |
Latest News for ELUT
GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, PhD, Chief Financial Officer, will present and host one-on-one meetings with investors at the Sidoti Small-Cap Virtual Investor Conference, taking place March 18–19, 2026.
GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”).
Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript
– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference call today at 5:00 p.m. ET / 2:00 p.m.
GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement set forth in Nasdaq…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ELUT.
U.S. House Trading
No House trades found for ELUT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.